Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.

“It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community,” said Bradley Burnam, Founder and CEO of Turn Therapeutics. “But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow.”

The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn’s growth and innovation. Further details about the blog will be announced later this week. The webinar series will provide live discussion covering ongoing programs, strategic milestones, and upcoming developments. The first live session will take place on Wednesday, October 22, 2025, at 2:00 PM ET via webcast.

Recordings and materials from webinars will be posted immediately following each session to the investor relations section of the company website.

October 22, 2025 live webinar:

Time: 2PM EST

Location: Click here to join

RSVP/Registration: Not required

About Turn Therapeutics

Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.

Where You Can Find Additional Information

Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://ir.turntherapeutics.com), filings we make with the Securities and Exchange Commission (the “SEC”), our corporate account on the social media platform X (formerly Twitter) (@hexagenhealing), LinkedIn, other social media platforms, webcasts, press releases and conference calls. We use these mediums to communicate with our shareholders and the public about our company and other matters. It is possible that the information that we make available in this manner may be deemed to be material information. We therefore encourage investors and others interested in our company to review this information.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. These statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company’s registration statement, the success of development programs, and the Company’s ability to execute its strategic plan. Further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these statements can be found in the Company’s SEC filings. Turn undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact: media@TurnTherapeutics.com
Investor Relations: investors@TurnTherapeutics.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.